NCT06134388View on ClinicalTrials.gov

Sulfasalazine in Patients With Metastatic Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Sulfasalazine

Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.

Trial Locations (1)

31527

RECRUITING

Tanta University Hospital, Tanta

All Listed Sponsors
lead

Tanta University

OTHER